Member Info for MickTKipper

DIXONS CARPHONE: Dixons Carphone DC.L, Britain's largest electricals and mobile phone retailer, beat forecasts with a 23 percent rise in first half profit, helped by a strong performance in its home market where it outperformed rivals....

DIXONS CARPHONE: Dixons Carphone DC.L, Britain's largest electricals and mobile phone retailer, beat forecasts with a 23 percent rise in first half profit, helped by a strong performance in its home market where it outperformed rivals....

UPDATE 1 – Dixons Carphone beats first – half profit forecasts on strong UK 16-12-2015 07:49 (Adds details, quote) LONDON, Dec 16 (Reuters) – Dixons Carphone , Britain's largest electricals and mobile phone retailer, beat forecasts with a 23 percent rise in first half profit, helped by a strong performance in its home market where it outperformed rivals. The group, which trades as Currys, PC World and Carphone Warehouse in the UK and Ireland, Elkjop and El Giganten in Nordic countries and Kotsovolos in Greece, said on Wednesday it made an underlying pretax profit of 121 million pounds ($182.00 million) in the 26 weeks to Oct. 31. That compares to analysts' average forecast of 111 million pounds, according to a company compiled consensus, and 98 million pounds made in the same period last year. Group sales at stores open over a year rose 5 percent, driven by a 7 percent rise in the UK & Ireland division. Dixons Carphone was formed through a merger last year of Dixons Retail and Carphone Warehouse and although investors initially reacted coolly to the plan, they have since been won over, with the shares up 37 percent. "Against a broadly flat market overall and a very strong comparative period we have seen continued like-for-like growth driven by market share gains across all territories," Chief Executive Sebastian James said. The firm said a strong "Black Friday" discount day on Nov. 27 delivered its biggest-ever single day's trade and was "a great start to Christmas." Dixons Carphone also announced changes to its board, with the addition of the former CEO of BT Ian Livingstone as deputy chairman and Tony DeNunzio, the former head of Asda/Walmart UK as senior independent director. Roger Taylor, the former CEO of Carphone Warehouse, will stand down as deputy chairman of the board with immediate effect. Shares in the firm, up 12 percent over the last year, closed Tuesday at 476.7 pence, valuing the business at 5.53 billion pounds. ($1 = 0.6648 pounds) (Reporting by James Davey; editing by Kate Holton) ((james.davey@thomsonreuters.com; +44 20 7542 7674; Reuters Messaging: james.davey.thomsonreuters.com@reuters.net) Keywords: DIXONS CARPHONE RESULTS/ © Thomson Reuters Limited. Click for restrictions

Dixons Carphone plc A strong half year with pro forma Headline profit before tax up 23% Interim results for the 26 weeks ended 31 October 2015 • Group H1 like-for-like revenue(3) up 5%; Q2 like-for-like up 3% • Market share gains across UK & Ireland, Nordics, Greece and Spain • Group pro forma Headline PBT(1) of £121m (14/15: £98m), up 23% • Group pro forma Headline EBIT(1) of £135m (14/15: £120m) • Group pro forma Headline basic EPS(1)(2) from continuing operations 7.5p (14/15: 6.3p) • Statutory profit before tax from continuing operations of £78m (14/15: £71m) after non-Headline charges of £43m (14/15: £31m), statutory basic EPS from continuing operations of 4.8p (14/15: 6.6p) • Interim dividend of 3.25p, payable in January 2016, an increase of 30% • CWS pipeline developing well and an encouraging start to the Sprint trial

Watch for broker upgrades.

<b>BTG plc 17.8% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 15th December 2015</b> BTG plc with EPIC/TICKER LON:BTG has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 755 GBX on its stock. This would imply the analyst believes there is now a potential upside of 17.8% from the opening price of 641 GBX. Over the last 30 and 90 trading days the company share price has increased 95.5 points and decreased 3 points respectively. BTG plc LON:BTG has a 50 day moving average of 584.88 GBX and the 200 Day Moving Average price is recorded at 669.43 GBX. The 1 year high share price is 835.87 GBX while the year low share price is currently 504 GBX. There are currently 382,957,017 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,454,754,479 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.

<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co. December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b> BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports. Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74). BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.

<b>BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase & Co. December 15th, 2015 • 0 comments • Filed Under • by ABMN Staff</b> BTG plc logoBTG plc (LON:BTG)‘s stock had its “overweight” rating reiterated by analysts at JPMorgan Chase & Co. in a research report issued on Tuesday, MarketBeat.com reports. Several other research firms have also issued reports on BTG. Jefferies Group lowered their price target on shares of BTG plc from GBX 950 ($14.32) to GBX 850 ($12.81) and set a “buy” rating on the stock in a research report on Thursday, September 17th. Stifel Nicolaus reissued a “hold” rating on shares of BTG plc in a research report on Monday. Deutsche Bank boosted their price target on shares of BTG plc from GBX 750 ($11.30) to GBX 755 ($11.38) and gave the company a “buy” rating in a research report on Monday. Finally, Panmure Gordon lowered their price target on shares of BTG plc from GBX 1,035 ($15.60) to GBX 800 ($12.06) and set a “buy” rating on the stock in a research report on Tuesday, November 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of GBX 779.20 ($11.74). BTG plc (LON:BTG) opened at 623.50 on Tuesday. The company’s market cap is GBX 2.38 billion. The company has a 50-day moving average of GBX 583.22 and a 200 day moving average of GBX 626.33. BTG plc has a 52 week low of GBX 504.00 and a 52 week high of GBX 835.87. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (LON:BTG) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins. The Company’s Specialty Pharmaceuticals segment offers a portfolio of antidote products that alleviate toxicity and treat rare conditions. The Company’s Licensing segment receives royalties relating to the sales of products that are subject to intellectual property and license agreements between the Company and various partners. The Company’s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd and BTG Employee Share Schemes Ltd, among others.

BTG broker views Date Broker Recommendation Price Old target price New target price Notes 15 Dec Deutsche Bank Buy 640.50 755.00 755.00 Reiterates 15 Dec JP Morgan Cazenove Overweight 640.50 - - Reiterates 14 Dec Jefferies International Buy 640.50 850.00 850.00 Reiterates 14 Dec Stifel Hold 640.50 - - Reiterates 14 Dec Deutsche Bank Buy 640.50 750.00 755.00 Reiterates

BTG plc (BTG) Receives Overweight Rating from JPMorgan Chase ... 43 minutes ago ... .......http://www.dakotafinancialnews.com/btg-plc-btg-receives-overweight-rating-from-jpmorgan-chase-co/727199/

DC. Dixons Carphone PLC Transfered from FAR9 thread. Went long on this one at 460p resistance end of NOV. Held through short term market volatility. Think this one will be a big hit amongst the xmas retailers. Word is property assets are going to be sold off which will boost the companys performance. Im very bullish on this one and think results are next week. http://content.screencast.com/users/marketsniper/folders/Default/media/7b466c92-fbd3-447d-a813-2ccdfc8ff45f/dc.%201.jpg

<b>BTG gets early approval on overdose antidote</b> Drug developer BTG (BTG) has received approval for its toxicity antidote drug Vistogard three months early. Deutsche Bank analyst Richard Parkes retained his ‘buy’ recommendation and upped his target price to 755p from 750p. The shares fell 1.5p to 623.5p yesterday. ‘Approval by the [US] Food and Drug Administration… provides a welcome positive surprise, coming three months ahead of the expected… action date,’ he said. ‘The decision makes it the only approved emergency treatment for accidental overdose or severe toxicity with the cancer treatments fluorouracil or capecitabine. ‘The drug will be marketed via BTG’s speciality pharmaceuticals division, which sells similar antidote therapies…to US hospitals and emergency rooms. Given synergies with BTG’s existing portfolio and sales force, we expect the launch to require minimal investment.’ http://citywire.co.uk/money/the-expert-view-rolls-royce-hammerson-and-cobham/a867279?ref=citywire-money-latest-news-list#i=3

BTG Broker Updates..... BTG PLC BTG Deutsche Bank Buy 623.50 623.50 755.00 755.00 Reiterates BTG PLC BTG JP Morgan Cazenove Overweight 623.50 623.50 - - Reiterate

<b>BTG plc 19.5% Potential Upside Indicated by Deutsche Bank Posted by: Ruth Bannister 14th December 2015</b> BTG plc with EPIC/TICKER LON:BTG had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 755 GBX on its stock. This indicates the analyst now believes there is a potential upside of 19.5% from today’s opening price of 632 GBX. Over the last 30 and 90 trading days the company share price has increased 85 points and decreased 10.5 points respectively. BTG plc LON:BTG has a 50 day moving average of 585.37 GBX and a 200 Day Moving Average share price is recorded at 670.05 GBX. The 52 week high for the stock is 835.87 GBX while the 52 week low is 504 GBX. There are currently 382,185,498 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,403,258,877 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.

BTG...... <b>UPDATE 1 – BTG gets triple dose of good news on new products 14-12-2015 11:21</b> (Adds comment from CEO and analyst, latest shares) LONDON, Dec 14 (Reuters) – Specialist medicine company BTG received a triple dose of good news on Monday as U.S. regulators approved two new treatments and a clinical trial of a novel lung device produced positive results. U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumours, and the success of PneumRx coils in severe emphysema may help counter recent disappointment over sales of BTG's varicose vein treatment Varithena. BTG Chief Executive Louise Makin said the positive developments demonstrated the company was delivering on its strategy to become a world-leading specialist healthcare business. The success of PneumRx coils removes a key remaining risk to the launch of the product in the United States, where it will now be filed for approval in mid-2016. Although Deutsche Bank analyst Richard Parkes said the benefit appeared only modest in the PneumRx coils study, as measured by the main outcome, secondary clinical results were strong. BTG shares, which have underperformed in recent months on concerns about sales of Varithena, were 0.8 percent higher at 630 pence by 1110 GMT. (Reporting by Ben Hirschler; Editing by Louise Heavens and Mark Potter) ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters Messaging: ben.hirschler.thomsonreuters.com@reuters.net) Keywords: BTG OUTLOOK/

BDEV Barratts UK housebuilders boosted by upbeat BoA ML note Mon 14 December 2015 10:59 Bank of America Merrill Lynch upgraded its stance on Barratt Developments to 'neutral' from 'underperform' as it took a look at UK housebuilders. <b><i>The bank said it remained supportive of the sector and reiterated buy-rated Persimmon, Taylor Wimpey and Bellway as its top picks. "We believe that housing supply will fail to keep up with long-term demand and that this is likely to result in modest house price inflation that in turn will more than offset cost pressures, allowing margins to expand albeit modestly. "With wages growing and interest rates benign, affordability is sufficient to maintain growth." As far as Barratt is concerned, it said market perception has improved over the last few years, which is likely to continue despite the recent change of management. Operationally, Barratt is performing well, particularly in the land market where anticipated returns on new developments have resulted in increased internal hurdle rates which bodes well for the direction of future revenues and earnings. "The three-year dividend plan sets out robust intentions and implies that the stock yields an attractive 5.6% in calendar 2016E," said ML. However, it added that the stock trades on a full price-to-earnings ratio currently and has one of the shortest land banks in the sector, which offsets the positives, hence the 'neutral' rating. It lifted its price target on the stock to 655p from 600p.</i></b> Merrill downgraded its target price on 'neutral' rated Bovis Homes to 1,000p from 1,190p to reflect the cost issues highlighted in the company's second half trading update. It said Bovis was suffering from a combination of planning delays on new high margin sites and higher-than-expected labour costs. http://content.screencast.com/users/marketsniper/folders/Default/media/46d45d8c-6da9-47d5-81ea-6ac909f7a6c6/bdev%201.jpg

<b>Home Retail Group Plc 56% Potential Upside Indicated by Nomura Posted by: Ruth Bannister 7th December 2015</b> Home Retail Group Plc with EPIC/TICKER LON:HOME has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Nomura. Home Retail Group Plc are listed in the Consumer Services sector within UK Main Market. Nomura have set a target price of 170 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 56% from the opening price of 109 GBX. Over the last 30 and 90 trading days the company share price has decreased 2.7 points and decreased 52.7 points respectively. Home Retail Group Plc LON:HOME has a 50 day moving average of 121.35 GBX and a 200 day moving average of 154.35 GBX. The 52 week high for the share price is currently at 219.38 GBX while the year low share price is currently 96.7 GBX. There are currently 815,092,075 shares in issue with the average daily volume traded being 3,805,945. Market capitalisation for LON:HOME is £893,340,902 GBP. Home Retail Group Plc is a United Kingdom-based home and general merchandise retailer. The Company’s segments include Argos, Homebase and Financial Services. Argos is a digital retailer, which sells products through its 755 stores, Website and mobile applications.

HILS Hill@Smith Holdings PLC Hill & Smith Holdings PLC FORECASTS 2015 2016 Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p) Panmure Gordon 04-12-15 HOLD 51.20 49.40 20.10 59.30 55.70 22.60 N+1 Singer 04-12-15 BUY 50.00 48.20 20.00 54.90 52.90 22.00 Arden Partners 04-12-15 BUY 49.40 48.13 20.00 55.00 53.59 22.00 Peel Hunt LLP 02-12-15 BUY 50.79 48.99 19.44 55.91 53.92 21.00 Investec Securities 17-11-15 BUY 50.50 48.64 20.00 53.30 50.75 21.50 Canaccord Genuity Ltd 06-10-15 BUY 50.70 49.70 20.00 54.80 53.50 22.00 Numis Securities Ltd 10-08-15 HOLD 50.00 48.10 20.00 54.40 50.60 22.00

<b>Barratt Developments Plc (BDEV) Receives “Buy” Rating from Deutsche Bank December 7th, 2015 • 0 comments • Filed Under • by ABMN Staff</b> Barratt Developments Plc logoBarratt Developments Plc (LON:BDEV)‘s stock had its “buy” rating reiterated by analysts at Deutsche Bank in a research report issued on Monday, AnalystRatings.NET reports.

Barratt Developments PLC BDEV Deutsche Bank Buy 613.50 613.50 - - Reiterates